Cerenome (PSTV) Other Non-Current Assets (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Other Non-Current Assets of $414000.0 for Q1 2026, up 2078.95% year-over-year from $19000.0 in Q1 2025, and up 5.08% quarter-over-quarter from $394000.0 in Q4 2025.
Cerenome (PSTV) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Other Non-Current Assets for 17 consecutive years, with $414000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 2078.95% year-over-year to $414000.0; the TTM figure through Mar 2026 stood at $414000.0 (up 2078.95% YoY), while the FY2025 annual figure was $394000.0, down 9.63% from the prior year.
- Other Non-Current Assets rose to $414000.0 in Q1 2026 per PSTV's latest filing, from $394000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $446000.0 in Q2 2025 and bottomed at $12000.0 in Q3 2022.
- Historically, Other Non-Current Assets has averaged $117294.1 across 5 years, with a median of $32000.0 in 2023.
- Annual changes were most pronounced in 2025 — Other Non-Current Assets plunged 40.62% — and 2026, when it surged 2078.95%.
- Plus Therapeutics' Other Non-Current Assets stood at $12000.0 in 2022, then surged by 166.67% to $32000.0 in 2023, then jumped by 1262.5% to $436000.0 in 2024, then dropped by 9.63% to $394000.0 in 2025, then advanced by 5.08% to $414000.0 in 2026.
- Business Quant data shows PSTV's Other Non-Current Assets at $414000.0 in Q1 2026, $394000.0 in Q4 2025, and $45000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 244,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 414,000.00 |
| Dec 31, 2025 | 394,000.00 |
| Sep 30, 2025 | 45,000.00 |
| Jun 30, 2025 | 446,000.00 |
| Mar 31, 2025 | 19,000.00 |
| Dec 31, 2024 | 436,000.00 |
| Sep 30, 2024 | 32,000.00 |
| Jun 30, 2024 | 32,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | 32,000.00 |
| Sep 30, 2023 | 32,000.00 |
| Jun 30, 2023 | 12,000.00 |
| Mar 31, 2023 | 12,000.00 |
| Dec 31, 2022 | 12,000.00 |
| Sep 30, 2022 | 12,000.00 |
| Jun 30, 2022 | 16,000.00 |
| Mar 31, 2022 | 16,000.00 |
| Dec 31, 2021 | 16,000.00 |
| Sep 30, 2021 | 16,000.00 |
| Jun 30, 2021 | 16,000.00 |